Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activation

Genes and Development

Volumn 29, Issue 14, 2015, Pages 1524-1534

  Zheng, Jiangge ^a   Lang, Yue ^a   Zhang, Qi ^a   Cui, Di ^a   Sun, Haili ^a   Jiang, Lun ^a   Chen, Zhenhang ^a   Zhang, Rui ^a   Gao, Yina ^a   Tian, Wenli ^b   Wu, Wei ^a   Tang, Jun ^a   Chen, Zhongzhou ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Cancer; Complex structure; Molecular basis; p53 activation; RPL11 MDM2

Indexed keywords

CYSTEINE; IMIDAZOLE; PROTEIN MDM2; PROTEIN P53; RIBOSOMAL PROTEIN L11; RIBOSOME PROTEIN; RNA 28S; UNCLASSIFIED DRUG; PROTEIN BINDING;

ARTICLE; CANCER INHIBITION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; GEL MOBILITY SHIFT ASSAY; GEL PERMEATION CHROMATOGRAPHY; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RIBOSOME; STATIC ELECTRICITY; WESTERN BLOTTING; ZINC FINGER MOTIF; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLIZATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; TRANSCRIPTION INITIATION;

AMINO ACID SEQUENCE; CRYSTALLIZATION; GENE SILENCING; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2; RIBOSOMAL PROTEINS; SEQUENCE ALIGNMENT; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84938073179     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.261792.115     Document Type: Article

References (45)

1. Anger AM, Armache JP, Berninghausen O, Habeck M, Subklewe M, Wilson DN, Beckmann R. 2013. Structures of the human and Drosophila 80S ribosome. Nature 497: 80-85.
2. Badhai J, Frojmark AS, Davey E, Schuster J, Dahl N. 2009. Ribosomal protein S19 and S24 insufficiency cause distinct cell cycle defects in Diamond-Blackfan anemia. Biochim Biophys Acta 1792: 1036-1042.
3. Ben-Shem A, Garreau de Loubresse N, Melnikov S, Jenner L, Yusupova G, Yusupov M. 2011. The structure of the eukaryotic ribosome at 3.0 Å resolution. Science 334: 1524-1529.
4. Bursac S, Brdovcak MC, Donati G, Volarevic S. 2014. Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis. Biochim Biophys Acta 1842: 817-830.
5. Donati G, Bertoni S, Brighenti E, Vici M, Trere D, Volarevic S, Montanaro L, Derenzini M. 2011. The balance between rRNA and ribosomal protein synthesis upand downregulates the tumour suppressor p53 in mammalian cells. Oncogene 30: 3274-3288.
6. Donati G, Peddigari S, Mercer CA, Thomas G. 2013. 5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint. Cell Rep 4: 87-98.
7. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR, et al. 2008. Identification of RPS14 as a 5q− syndrome gene by RNA interference screen. Nature 451: 335-339.
8. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66: 486-501.
9. Fumagalli S, Thomas G. 2011. The role of p53 in ribosomopathies. Semin Hematol 48: 97-105.
10. Fumagalli S, Di Cara A, Neb-Gulati A, Natt F, Schwemberger S, Hall J, Babcock GF, Bernardi R, Pandolfi PP, Thomas G. 2009. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol 11: 501-508.
11. Fumagalli S, Ivanenkov VV, Teng T, Thomas G. 2012. Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to the activation of a novel G2/M checkpoint. Genes Dev 26: 1028-1040.
12. Gagnon MG, Lin J, Bulkley D, Steitz TA. 2014. Crystal structure of elongation factor 4 bound to a clockwise ratcheted ribosome. Science 345: 684-687.
13. Gilkes DM, Chen J. 2007. Distinct roles of MDMX in the regulation of p53 response to ribosomal stress. Cell Cycle 6: 151-155.
14. Gilkes DM, Chen L, Chen J. 2006. MDMX regulation of p53 response to ribosomal stress. EMBO J 25: 5614-5625.
15. Holzel M, Orban M, Hochstatter J, Rohrmoser M, Harasim T, Malamoussi A, Kremmer E, Langst G, Eick D. 2010. Defects in 18 S or 28 S rRNA processing activate the p53 pathway. J Biol Chem 285: 6364-6370.
16. Honda R, Yasuda H. 2000. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19: 1473-1476.
17. Kim TH, Leslie P, Zhang Y. 2014. Ribosomal proteins as unrevealed caretakers for cellular stress and genomic instability. Oncotarget 5: 860-871.
18. Krissinel E, Henrick K. 2007. Inference of macromolecular assemblies from crystalline state. J Mol Biol 372: 774-797.
19. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
20. Lai K, Amsterdam A, Farrington S, Bronson RT, Hopkins N, Lees JA. 2009. Many ribosomal protein mutations are associated with growth impairment and tumor predisposition in zebrafish. Dev Dyn 238: 76-85.
21. Li M, Gu W. 2011. A critical role for noncoding 5S rRNA in regulating Mdmx stability. Mol cell 43: 1023-1032.
22. Lindstrom MS, Jin A, Deisenroth C, White Wolf G, Zhang Y. 2007. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol Cell Biol 27: 10561068.
23. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH. 2003. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3: 577-587.
24. Long F, Vagin AA, Young P, Murshudov GN. 2008. BALBES: a molecular-replacement pipeline. Acta Crystallogr D Biol Crystallogr 64: 125-132.
25. Macias E, Jin A, Deisenroth C, Bhat K, Mao H, Lindstrom MS, Zhang Y. 2010. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 interaction. Cancer Cell 18: 231-243.
26. Marine JC, Dyer MA, Jochemsen AG. 2007. MDMX: from bench to bedside. J Cell Sci 120: 371-378.
27. Miliani de Marval PL, Zhang Y. 2011. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget 2: 234-238.
28. Montes de Oca Luna R, Wagner DS, Lozano G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
29. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F, Vagin AA. 2011. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 67: 355-367.
30. Ozaki T, Nakagawara A. 2011. Role of p53 in cell death and human cancers. Cancers (Basel) 3: 994-1013.
31. Pant V, Xiong S, Jackson JG, Post SM, Abbas HA, Quintas-Cardama A, Hamir AN, Lozano G. 2013. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev 27: 1857-1867.
32. Sheldrick GM. 2008. A short history of SHELX. Acta Crystallogr A 64: 112-122.
33. Sherr CJ. 2006. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663-673.
34. Sloan KE, Bohnsack MT, Watkins NJ. 2013. The 5S RNP couples p53 homeostasis to ribosome biogenesis and nucleolar stress. Cell Rep 5: 237-247.
35. Teng T, Thomas G, Mercer CA. 2013. Growth control and ribosomopathies. Curr Opin Genet Dev 23: 63-71.
36. Tollini LA, Jin A, Park J, Zhang Y. 2014. Regulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damage. Cancer Cell 26: 235-247.
37. Vlachos A, Rosenberg PS, Atsidaftos E, Alter BP, Lipton JM. 2012. IncidenceofneoplasiainDiamondBlackfananemia:areportfrom theDiamondBlackfanAnemiaRegistry.Blood 119:3815-3819.
38. Vousden KH, Prives C. 2009. Blinded by the light: the growing complexity of p53. Cell 137: 413-431.
39. Wade M, Li YC, Wahl GM. 2013. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13: 83-96.
40. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, et al. 2011. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67: 235-242.
41. Yu GW, Allen MD, Andreeva A, Fersht AR, Bycroft M. 2006. Solution structure of the C4 zinc finger domain of HDM2. Protein Sci 15: 384-389.
42. Zhang Y, Lu H. 2009. Signaling to p53: ribosomal proteins find their way. Cancer Cell 16: 369-377.
43. Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA, Xiong Y. 2003. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 23: 8902-8912.
44. Zhang Q, Xiao H, Chai SC, Hoang QQ, Lu H. 2011. Hydrophilic residues are crucial for ribosomal protein L11 (RPL11) interaction with zinc finger domain of MDM2 and p53 protein activation. J Biol Chem 286: 38264-38274.
45. Zhou X, Liao JM, Liao WJ, Lu H. 2012. Scission of the p53-MDM2 loop by ribosomal proteins. Genes Cancer 3: 298-310.